Evidence map›Paper›PMID 36003386›Full record

ArticleFrontiers in immunology2022

Colon metastasis from lung adenocarcinoma with BRAF V600E mutation: A case report.

Yuhao Luo, Kelin Mou, Jianmei Wang, Jing Luo, Lin Peng, Hua Ye, Sheng Lin

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yuhao LuoDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Kelin MouDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Jianmei WangDepartment of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Jing LuoDepartment of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Lin PengDepartment of Bone and Joint, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Hua YeDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Sheng LinDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Affiliated Hospital of Southwest Medical University · CNFirst Affiliated Hospital of Sichuan Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Symptomatic colon metastasis from primary lung cancer is rare in clinical practice. We report the case of a 58-year-old patient with advanced lung adenocarcinoma who developed abdominal symptoms, including abdominal distention and difficulty defecating, after immunotherapy and chemotherapy. The patient was diagnosed with lung adenocarcinoma, and systemic positron emission tomography-computed tomography confirmed multiple lymph node, pleural, and adrenal metastases. Molecular detection indicated BRAF V600E mutation and high programmed death-ligand 1 (PD-L1) expression. After first-line anti-programmed cell death protein 1 immunotherapy combined with chemotherapy, the nodes in the chest remarkably diminished. However, it was followed by colon obstruction, incomplete ileus, and bone metastasis. Endoscopic histological examination confirmed adenocarcinoma but could not identify primary or secondary tumors due to insufficient tissue. We performed colon resection to remove the obstruction, and postoperative tissue pathological microscopy confirmed metastasis from the lung adenocarcinoma. We corroborated the BRAF V600E mutation and high PD-L1 expression and supported the molecular features of lung adenocarcinoma. During hospitalization, the patient presented with unbearable pain in the bone metastases, and palliative radiotherapy was administered. Then, the patient received dabrafenib plus trametinib as the second-line therapy. This report discusses the clinical characteristics, pathology, imaging, molecular profile assessments, and treatment of primary lung adenocarcinoma with colon metastasis.

Indexed as

Adenocarcinoma of LungColonic NeoplasmsLung NeoplasmsRectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenHumansImidazolesMiddle AgedMutationOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonesB7-H1 AntigenBRAF protein, humanImidazolesOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonesbraf v600ecolon metastasisimmunotherapynsclcpd-1

Identifiers

PMID36003386
PMCPMC9393296
OpenAlexW4290546066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.